Table 3.
Associations of FGF23 with eGFR <60 mL/min/1.73 m2 or albuminuria >30 mg/24 h as individual outcomes
| Sex-specific tertiles of FGF23 (RU/mL), median (IQR) |
||||||
|---|---|---|---|---|---|---|
| ♂: <61.9 | ♂: 61.9–74.2 | ♂: >74.2 | ||||
| Model | ♀: <58.4 | ♀: 58.4–82.9 | ♀: >82.9 | |||
| Ptrend | Log2FGF23 (continuous), median (IQR) | P-value | ||||
| eGFR <60 mL/min/1.73 m2 (n = 198) | ||||||
| 1 | 1.0 (Ref) | 1.87 (1.21–2.86) | 3.48 (2.48–5.18) | <0.001 | 1.52 (1.30–1.79) | <0.001 |
| 2 | 1.0 (Ref) | 1.87 (1.22–2.87) | 3.09 (2.08–4.59) | <0.001 | 1.71 (1.45–2.01) | <0.001 |
| 3 | 1.0 (Ref) | 1.38 (1.11–1.72) | 1.73 (1.41–2.13) | 0.006 | 1.25 (1.12–1.38) | 0.03 |
| 4 | 1.0 (Ref) | 1.38 (0.89–2.15) | 1.67 (1.10–2.55) | 0.03 | 1.25 (1.01–1.55) | 0.04 |
| 5 | 1.0 (Ref) | 1.38 (0.89–2.14) | 1.67 (1.08–2.55) | 0.02 | 1.28 (1.00–1.62) | 0.048 |
| Albuminuria >30 mg/24 h (n = 442) | ||||||
| 1 | 1.0 (Ref) | 0.99 (0.78–1.25) | 1.41 (1.12–1.76) | 0.001 | 1.21 (1.06–1.37) | 0.004 |
| 2 | 1.0 (Ref) | 0.95 (0.74–1.20) | 1.27 (1.01–1.58) | 0.03 | 1.29 (1.13–1.47) | <0.001 |
| 3 | 1.0 (Ref) | 0.93 (0.73–1.18) | 1.14 (1.01–1.28) | 0.19 | 1.19 (1.10–1.27) | 0.01 |
| 4 | 1.0 (Ref) | 0.93 (0.73–1.19) | 1.13 (0.90–1.44) | 0.20 | 1.17 (1.02–1.34) | 0.02 |
| 5 | 1.0 (Ref) | 0.94 (0.74–1.20) | 1.16 (0.91–1.49) | 0.17 | 1.24 (1.06–1.45) | 0.01 |
Model 1, unadjusted model; Model 2, Model 1 + adjustment for age and sex; Model 3, Model 2 + adjustment for mean arterial blood pressure, the use of antihypertensive drugs, BMI, ethnicity, smoking status, eGFRCKD-EPI and albuminuria; Model 4, Model 3 + adjustment for total cholesterol, history of diabetes, serum phosphate, calcium and plasma PTH, 25(OH)D, hsCRP and 24-h urinary urea excretion; Model 5, Model 4 + adjustment for serum iron, transferrin and ferritin.